DV Biomed Co., Ltd. (TPEX:6539)
Taiwan · Delayed Price · Currency is TWD 59.00
+1.50 (2.61%)
At close: Feb 11, 2026
DV Biomed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 712.61 | 573.57 | 618.85 | 1,866 | 1,827 | 1,812 | |
Revenue Growth (YoY) | 22.75% | -7.32% | -66.84% | 2.13% | 0.85% | -6.15% |
Cost of Revenue | 200.86 | 149.07 | 135.5 | 827.29 | 804.96 | 886.25 |
Gross Profit | 511.75 | 424.5 | 483.35 | 1,039 | 1,022 | 925.51 |
Selling, General & Admin | 426.53 | 310.89 | 325.03 | 639.72 | 592.92 | 623.98 |
Research & Development | 4.72 | 5.28 | 8.25 | 12.84 | 12.44 | 31.95 |
Operating Expenses | 431.18 | 314.88 | 334.39 | 651.96 | 603.57 | 657.77 |
Operating Income | 80.57 | 109.63 | 148.96 | 386.91 | 418.65 | 267.74 |
Interest Expense | -2.32 | -1.68 | -0.16 | -5.21 | -4.45 | -4.78 |
Interest & Investment Income | 7.16 | 5.44 | 6.01 | 2.22 | 0.83 | 0.68 |
Earnings From Equity Investments | - | - | - | -26.15 | -27.97 | -24.74 |
Currency Exchange Gain (Loss) | -21.03 | - | - | - | -0.1 | -0.93 |
Other Non Operating Income (Expenses) | 11.51 | 12.42 | 6.32 | 7.28 | -2.55 | -3.63 |
EBT Excluding Unusual Items | 75.88 | 125.81 | 161.13 | 365.06 | 384.42 | 234.34 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.3 | 0.14 |
Gain (Loss) on Sale of Assets | -0.45 | - | - | - | -4.73 | 96.79 |
Asset Writedown | - | - | - | - | 13.91 | - |
Other Unusual Items | - | - | - | - | 1.87 | 5.29 |
Pretax Income | 75.44 | 125.81 | 161.13 | 365.06 | 395.76 | 336.55 |
Income Tax Expense | 12.57 | 23.19 | 30.17 | 76.06 | 91.19 | 51.87 |
Earnings From Continuing Operations | 62.87 | 102.62 | 130.97 | 289 | 304.58 | 284.68 |
Earnings From Discontinued Operations | -0.54 | -0.83 | 9.34 | -7.74 | - | - |
Net Income to Company | 62.34 | 101.79 | 140.3 | 281.26 | 304.58 | 284.68 |
Minority Interest in Earnings | -9.95 | -12.71 | 22.61 | - | - | 16.72 |
Net Income | 52.39 | 89.08 | 162.91 | 281.26 | 304.58 | 301.4 |
Net Income to Common | 52.39 | 89.08 | 162.91 | 281.26 | 304.58 | 301.4 |
Net Income Growth | -53.60% | -45.32% | -42.08% | -7.66% | 1.05% | 81.26% |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 25 | 25 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 25 | 25 |
Shares Change (YoY) | -0.18% | -0.16% | -0.17% | -0.76% | -0.81% | -0.82% |
EPS (Basic) | 2.15 | 3.66 | 6.69 | 11.51 | 12.37 | 12.14 |
EPS (Diluted) | 2.04 | 3.65 | 6.67 | 11.49 | 12.35 | 12.13 |
EPS Growth | -56.00% | -45.23% | -41.97% | -6.94% | 1.82% | 82.65% |
Free Cash Flow | 131.7 | 117.52 | 67.09 | 401.83 | 460.37 | 369.77 |
Free Cash Flow Per Share | 5.41 | 4.82 | 2.75 | 16.43 | 18.68 | 14.88 |
Dividend Per Share | 1.525 | 2.373 | 7.367 | 13.014 | 10.590 | 9.628 |
Dividend Growth | -71.41% | -67.79% | -43.40% | 22.89% | 10.00% | 146.96% |
Gross Margin | 71.81% | 74.01% | 78.11% | 55.67% | 55.95% | 51.08% |
Operating Margin | 11.31% | 19.11% | 24.07% | 20.73% | 22.91% | 14.78% |
Profit Margin | 7.35% | 15.53% | 26.32% | 15.07% | 16.67% | 16.64% |
Free Cash Flow Margin | 18.48% | 20.49% | 10.84% | 21.53% | 25.20% | 20.41% |
EBITDA | 83.74 | 114.3 | 160.47 | 468.9 | 542.47 | 360.43 |
EBITDA Margin | 11.75% | 19.93% | 25.93% | 25.13% | 29.69% | 19.89% |
D&A For EBITDA | 3.17 | 4.68 | 11.51 | 81.99 | 123.82 | 92.69 |
EBIT | 80.57 | 109.63 | 148.96 | 386.91 | 418.65 | 267.74 |
EBIT Margin | 11.31% | 19.11% | 24.07% | 20.73% | 22.91% | 14.78% |
Effective Tax Rate | 16.66% | 18.43% | 18.72% | 20.83% | 23.04% | 15.41% |
Advertising Expenses | - | - | - | - | 185.85 | 214.09 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.